- A nationwide prospective cohort study from Denmark suggests that women using hormonal contraceptives are not at increased risk of pancreatic cancer.
Why this matters
- A prior prospective cohort study had shown a 72% increased risk of pancreatic cancer in long-term users of hormonal contraception.
- 235 pancreatic cancers occurred among 1.9 million women over an average of 11.4 years of follow-up (12.9 million person-years of hormonal contraceptive use).
- Hormonal contraception users had similar risk of pancreatic cancer as never-users (relative risk [RR], 0.90; 95% CI, 0.68-1.19).
- Long-term use (>10 years) was also not significantly associated with risk of pancreatic cancer (RR, 0.83; 95% CI, 0.47-1.50).
- Current or recent use of progestin-only contraception and combined oral contraception also shows a similar risk of pancreatic cancer as never use (RR, 1.16 [95% CI, 0.79-1.89] and 0.92 [95% CI, 0.62-1.36], respectively).
- 1.9 million women from the Danish National Prescription Registry, Danish Cancer Registry, and Danish National Patient Register were analyzed for associations between hormonal contraceptive use and pancreatic cancer.
- Funding: Novo Nordisk Foundation.
- No adjustment for alcohol consumption and dietary factors.